Article Text

Download PDFPDF
Randomised controlled trial
Whether the use of unopposed oestrogen following a myocardial infarction is beneficial or harmful remains unclear, and in individual women the effects may vary according to the underlying risk profile

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests SS has in the past consulted, and presently consults with, Bayer Schering and with other manufacturers of female hormones.

  • Provenance and peer review Not commissioned; internally peer reviewed.